Number of pages: 100 | Report Format: PDF | Published date: March 16, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
According to the deep-dive market assessment study by Growth Plus Reports, the global refractory/relapsed B-cell and T-cell lymphoma market was valued at US$ 1.66 billion in 2022 and is expected to register a revenue CAGR of 8.93% to reach US$ 3.59 billion by 2031.
Refractory/Relapsed B-cell and T-cell Lymphoma Market Fundamentals
Lymphoma is a type of cancer that affects the lymphatic system, a part of the immune system. Refractory lymphoma refers to lymphoma that does not respond to initial treatment or responds but then stops responding to treatment. Relapsed lymphoma refers to lymphoma that has reoccurred after a period of remission. In either case, additional or alternative treatments can be crucial to control the cancer cells and improve the patient’s prognosis. These may include additional chemotherapy, radiation therapy, immunotherapy, targeted therapy, stem cell transplant, or a combination of these approaches. The choice of treatment depends on the type of lymphoma, the stage of the disease, the patient’s overall health, and other factors. B-cell and T-cell refractory/relapsed lymphoma refer to a type of non-Hodgkin lymphoma that either does not respond to initial treatment or relapses after a period of remission. B-cell and T-cell lymphomas arise from B-cells and T-cells, which are white blood cells that play an important role in the immune system. However, the T-cell type of lymphoma can be particularly challenging to treat because T-cell lymphomas are relatively rare, with minimum knowledge and available treatment than B-cell lymphomas.
Refractory/Relapsed B-cell and T-cell Lymphoma Market Dynamics
Continuous technical advancements by leading market players globally and research and development of innovative medication treatments are some of the primary factors driving market revenue growth. Additionally, the rising frequency of refractory/relapsed B-cell and T-cell lymphoma, as well as increasing government and commercial research expenditures for developing better medications and therapy choices, are contributing to an increase in patient compliance and survival rates. As the frequency of various cancer forms rises, finding more effective and sophisticated treatment alternatives is becoming increasingly vital. International players consistently work on research and development initiatives to produce improvised and highly effective pharmaceuticals. Many devices linked to advanced medication delivery systems are in the works and are seeking FDA (Food and Drug Administration) approval. High demand for mode sophisticated drugs to treat refractory/relapsed B-cell and T-cell lymphoma is projected to boost market revenue growth.
However, the high cost of therapy for refractory/relapsed B-cell and T-cell lymphoma is one of the primary reasons that may limit market revenue development to some extent since it discourages certain patients from seeking treatment. Relapsed-Refractory B-cell and T-cell lymphoma treatment can be costly, even when only first- and second-line medicines are considered, costing up to US$ 200,000.
Refractory/Relapsed B-cell and T-cell Lymphoma Market Ecosystem
The global refractory/relapsed B-cell and T-cell lymphoma market has been analyzed from three perspectives: type, therapy, and region.
Refractory/Relapsed B-cell and T-cell Lymphoma Market by Type
Based on the type, the global refractory/relapsed B-cell and T-cell lymphoma market can be further segmented into B-cell lymphoma and T-cell lymphoma.
Refractory B-cell lymphoma is a type of blood cancer that occurs when B cells, a type of white blood cell, become abnormal and grow uncontrollably. The incidence of refractory B-cell lymphoma is increasing, driving the demand for effective treatments. Technological advancements have also led to new treatments for refractory B-cell lymphoma, including targeted therapies, immunotherapies, and combination therapies. Moreover, the regulatory environment for drug development has become more favorable, with expedited approval processes for promising treatments. Pharmaceutical companies are investing heavily in research and development to discover and develop new therapies for refractory B-cell lymphoma. The increasing healthcare expenditure by governments and private organizations is expected to increase the availability of advanced treatments for refractory B-cell lymphoma. A growing awareness among patients and healthcare professionals about the importance of early diagnosis and treatment of refractory B-cell lymphoma is expected to drive market revenue growth.
Refractory/Relapsed B-cell and T-cell Lymphoma Market by Therapy
Based on the region, the global refractory/relapsed B-cell and T-cell lymphoma market can be further segmented into monotherapy and combination therapy.
The combination therapy segment accounts for the largest revenue share in the global market. Combination therapy can improve treatment efficacy by targeting multiple mechanisms of action, enhancing overall response rates. Using combination therapy can also help reduce the likelihood of drug resistance. When cancer cells develop resistance to a single drug, they can often still be targeted by another drug with a different mechanism of action. Combination therapy allows for more flexible dosing schedules. This can be particularly important in cases where one or more drugs have significant toxicity or side effects. Adjusting the dosing schedule can help reduce toxicity while still maintaining efficacy. By using different drugs with different mechanisms of action, combination therapy can target different aspects of cancer, such as its growth and survival pathways, making it harder for cancer cells to survive and proliferate.
In some cases, the combination of drugs may lead to synergistic effects, where the combined effect of the drugs is greater than the sum of their individual effects. Thus, all these factors are responsible for the growth of combination therapy, thereby propelling the global market. However, combination therapies can be more complex to administer, requiring more frequent monitoring and potentially more resources.
The monotherapy segment is expected to grow steadily during the forecast period. Monotherapy is often used to treat refractory B-cell lymphoma because it has several advantages over combination therapies. This monotherapy can be less toxic than combination therapy, as it typically involves a single drug with a specific mechanism of action. Additionally, this type of therapy is often more cost-effective than combination therapy, as it requires fewer drugs and can be administered more easily. Lastly, some studies have shown that monotherapy can be as effective as combination therapy in treating refractory B-cell lymphoma. This is because the single drug used in monotherapy may be highly targeted to the specific type of lymphoma being treated, whereas combination therapy may be less specific. Monotherapy is often safer, more cost-effective, and more effective than combination therapy. However, the choice of therapy ultimately depends on the individual patient’s condition and specific treatment goals.
Refractory/Relapsed B-cell and T-cell Lymphoma Market by Region
Based on the region, the global refractory/relapsed B-cell and T-cell lymphoma market can be further segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounts for the largest revenue share in the market. North America’s well-established healthcare infrastructure includes modern hospitals, specialized clinics, and well-trained healthcare professionals. This infrastructure provides a favorable environment for developing and adopting innovative treatment options for refractory/relapsed B-cell and T-cell lymphoma. The incidence of B-cell lymphoma is higher in North America than in other regions. This high prevalence has resulted in a greater demand for effective treatments for refractory/relapsed B-cell and T-cell lymphoma, driving the market revenue growth in this region. North America has a culture of early adoption of novel therapies, and the regulatory agencies in the region have supported the development of new treatments for refractory B-cell lymphoma. This has led to the availability of several novel therapies in North America, which has helped to drive market revenue growth in this region. The reimbursement policies for cancer treatments in North America are generally more favorable than in other regions. This has encouraged the developing and adopting of innovative treatments for refractory B-cell lymphoma in this region. North America has a strong research and development infrastructure, which includes academic institutions, pharmaceutical companies, and biotech firms. This infrastructure has enabled the development of several novel therapies for refractory B-cell lymphoma, which has driven market revenue growth in this region.
Europe accounts for the second-largest revenue share in the global refractory/relapsed B-cell and T-cell market. The market revenue growth in this region can be attributed to well-developed healthcare facilities, infrastructure, and the overall healthcare system. Additionally, the rapid adoption of advanced technologies, the high amount of healthcare expenditure, and growing government and/or private awareness initiatives further fuel the market revenue growth in this region.
Asia Pacific is a developing region in this market. This can be ascribed to expanding healthcare infrastructure, rising vaccination rates, and many other factors. The refractory/relapsed B-cell and T-cell lymphoma therapy market is also expanding due to rising research and development efforts and rising healthcare spending in the region.
Refractory/Relapsed B-cell and T-cell Lymphoma Market Competitive Landscape
The prominent players operating in the global refractory/relapsed B-cell and T-cell lymphoma market are:
Refractory/Relapsed B-cell and T-cell Lymphoma Market Strategic Developments
B-cell and T-cell refractory/relapsed lymphoma refer to a type of non-Hodgkin lymphoma (NHL) that either does not respond to initial treatment or relapses after a period of remission.
The growing research and development activities for the development and launch of novel drugs or treatments is driving the refractory/relapsed B-cell and T-cell lymphoma market.
Key companies operating the global refractory/relapsed B-cell and T-cell lymphoma market include Step Pharma SAS, Bristol-Myers Squibb Company, Hrain Biotechnology Co. Ltd., and CRISPR Therapeutics AG.
Lack of awareness and limited treatment options restrict market revenue growth.
The global refractory/relapsed B-cell and T-cell lymphoma market is expected to register a revenue CAGR of 8.93% during the forecast period.
*Insights on financial performance are subject to the availability of information in the public domain